FDA approves Merck’s oral cholesterol drug enlicitide, to be sold as Lipfendra
The Facts
- The FDA approved enlicitide on Thursday, and Merck will market it under the brand name Lipfendra.
- Lipfendra is a once-daily pill and the first oral drug in the PCSK9 inhibitor class to receive FDA approval.
- The drug is intended for adults with high LDL cholesterol, including some patients whose cholesterol remains elevated despite other treatment.
- Lipfendra works by inhibiting the PCSK9 protein, which helps the body clear LDL cholesterol from the blood.
- Before this approval, PCSK9 inhibitors were available primarily as injectable drugs rather than pills.
- Clinical trials reported by multiple outlets found that adding Lipfendra to statin therapy reduced LDL cholesterol by about 56% to 60%.
- The approval matters because it gives patients a needle-free alternative to injectable PCSK9 drugs, which several reports say are more expensive and may be less convenient for some people.
- An unresolved question is whether the LDL reductions seen with Lipfendra will also reduce heart attacks or strokes; Merck is conducting an ongoing outcomes study.
Context
How is Lipfendra different from statins?
Statins lower cholesterol by reducing the liver’s production of cholesterol, while Lipfendra is a PCSK9 inhibitor that helps the liver remove more LDL cholesterol from the bloodstream. Reports also describe Lipfendra as an option for patients who need additional LDL lowering beyond what statins alone can provide. NYT,Indian Express,Guardian
Who is the new pill meant for?
Sources say the drug is approved for adults with high LDL cholesterol, including patients with hypercholesterolemia and some hereditary forms such as heterozygous familial hypercholesterolemia. It is described as an add-on to diet, exercise, and other LDL-lowering therapies. Fox News,NY Post,Drugs.com
What do we know about cost and availability?
Multiple reports say Merck expects Lipfendra to reach pharmacies within weeks. Pricing reports put the monthly list price at about $300 to $315, below the roughly $500 to $600 monthly list prices cited for comparable injectable PCSK9 drugs. NYT,Aol,U.S. News & World R…
Where Left and Right agree, and where they split
- Where Left and Right agree
- A first oral PCSK9 inhibitor gives adults with high LDL cholesterol a needle-free new option, even as its effect on heart attacks or strokes remains unproven.
- Where Left and Right split
- Whether the story is about expanding practical access to cholesterol treatment, or about withholding full confidence until lower LDL is shown to prevent heart attacks or strokes.
How left and right read it
What matters most is who gets a realistic shot at treatment. A once-daily, needle-free option for adults with high LDL cholesterol, including some whose levels stay elevated despite other treatment, could ease the burden created by injectable drugs that several reports say are more expensive and less convenient for some people. The big equity question now is whether the LDL gains seen alongside statins will translate into fewer heart attacks or strokes.
“Los pacientes que necesitan reducir su colesterol pronto tendrán una nueva y potente opción.” — The New York Times
What matters most is disciplined judgment: the FDA approved a new option, but an important question is still unresolved. Lipfendra is the first oral PCSK9 inhibitor and offers adults with high LDL cholesterol a once-daily alternative in a category that was primarily injectable, yet the ongoing outcomes study means the case that matters most is not just lower LDL, but whether that actually reduces heart attacks or strokes.
“Lipfendra is a game changer, with a price of $315 for a 30-day supply and without the pain of injection.” — The Daily Wire
The receipts — all 100 sources
Wire services (7)
Independent coverage (50)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.